Sievert, Theodor http://orcid.org/0009-0009-9630-2540
Didriksson, Ingrid
Spångfors, Martin
Lilja, Gisela
Blennow, Kaj
Zetterberg, Henrik
Frigyesi, Attila
Friberg, Hans
Funding for this research was provided by:
Hjärt-Lungfonden (2022-0352, 2022-0458, 2021-10233)
Region Skåne (2022:YF0009)
Region Skåne (2022-0226)
Lund University
Article History
Received: 15 July 2023
Accepted: 6 September 2023
First Online: 28 September 2023
Declarations
:
: TS, ID, MS, GL, KB, AF, and HF declare no competing interests. HZ has served on scientific advisory boards or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave. In addition, HZ has given lectures at symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
: Ethical approval and consent to participate: Ethical approval was acquired from the Swedish Ethical Review Authority (2020/01955, 2020/03483 and 2020/05233). Written informed consent was obtained from all surviving participants on admission, before discharge or at follow-up. For deceased patients, consent was presumed according to the approval from the Ethical Review Authority. Trial registration: NCT04974775. Registered 23rd July 2021—retrospectively registered, link.
: Not applicable.